Does the flap of a butterfly's wings in Brazil set off a Tornado in Texas? - The JC virus story in multiple sclerosis

Israel Medical Association Journal

Volumn 7, Issue 5, 2005, Pages 283-285

  Achiron, Anat ^a,b   Miron, Shmuel ^a,b   Shoenfeld, Yehuda ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Immunosupression; Interferon beta 1a; JC virus; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy

Indexed keywords

ALPHA4 INTEGRIN; AZATHIOPRINE; BETA1A INTERFERON; BETA7 INTEGRIN; CIDOFOVIR; CYTARABINE; NATALIZUMAB; VIRUS DNA;

ARTICLE; CLINICAL TRIAL; CROHN DISEASE; CROSS REACTION; DIFFERENTIAL DIAGNOSIS; DRUG APPROVAL; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNOCYTOCHEMISTRY; JC VIRUS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; VIRUS INFECTION; VIRUS REACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS;

EID: 18744384963     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Vollmer TL, JT Phillips, Goodman AD, et al. An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis. Mult Scler 2004;10:511-20.
2. Ursell MR, O'Connor PW. Natalizumab and other monoclonal antibodies. Neurol Clin 2005;23:233-46.
3. Stuart WH, Cohan S, Richert JR, Achiron A. Selecting a disease-modifying agent as platform therapy in the long-term management of multiple sclerosis. Neurology 2004;63(11 Suppl 5):S19-27.
4. Padgett BL, Walker DL, ZuRhein GM, Eckroade RJ, Dessel BH. Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1971;i:1257-60
5. Barbanti-Brodano G, Martini F, De Mattei M, Lazzarin L, Corallini A, Tognon M. BK and JC human polyomaviruses and simian virus 40: natural history of infection in humans, experimental oncogenicity, and association with human tumors. Adv Virus Res 1998;50:69-99.
6. Safak M, Khalili K. An overview: Human polyomavirus JC virus and its associated disorders. J Neurovirol 2003;9(Suppl 1):3-9
7. Padgett BL, Walker DL. Prevalence of antibodies in human sera against: JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973;127:467-70.
8. Du Pasquier RA, Schmitz JE, Jean-Jacques J, et al. Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. J Virol 2004;78:10206-10.
9. Aksamit AJ. Progressive multifocal leukoencephalopathy: a review of the pathology and pathogenesis. Microsc Res Tech 1995;32:302-11.
10. Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 2004;17:365-70.
11. Berger JR. Progressive multifocal leukoencephalopathy in acquired immunodeficiency syndrome: explaining the high incidence and disproportionate frequency of the illness relative to other immunosuppressive conditions. J Neurovirol 2003;9 (Suppl 1):38-41
12. Dorries K, Sbiera S, Drews K, Arendt G, Eggers C, Dorries R. Association of human polyomavirus JC with peripheral blood of immunoimpaired and healthy individuals. J Neurovirol 2003;9 (Suppl 1):81-7.
13. Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 2002;186 (Suppl 2):S180-6.
14. Richardson-Burns SM, Kleinschmidt-DeMasters BK, DeBiasi RL, Tyler KL. Progressive multifocal leukoencephalopathy and apoptosis of infected oligodendrocytes in the central nervous system of patients with and without AIDS. Arch Neurol 2002;59:1930-6.
15. Hou J, Major EO. Progressive multifocal leukoencephalopathy: JC virus induced demyelination in the immune compromised host. J Neurovirol 2000;6 (Suppl 2):S98-100.
16. Dworkin MS. A review of progressive multifocal leukoencephalopathy in persons with and without AIDS. Curr Clin Top Infect Dis 2002:22:181-95.
17. Bossolasco SG, Calori F, Moretti A, et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis 2005;40:738-44.
18. Wyen C, Hoffmann C, Schmeier N, et al. Progressive multifocal leukoencephalopathy in patients on highly active antiretroviral therapy-survival and risk factors of death. J Acquir Immune Defic Syndr 2004;37: 1263-8.
19. De Luca A, Giancola ML, Ammassari A, et al. Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study. J Neurovirol 2001;7:364-8.
20. McCormack PL, Scott LJ. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis. CNS Drugs 2004;18:521-46.
21. Bach MA, Bach JF. Activities of immunosuppressive agents in vitro. II: Different timing of azathioprine and methotrexate in inhibition and stimulation of mixed lymphocyte reaction. Clin Exp Immunol 1972;11:89-98.
22. Gasnault J, Kahraman M, de Goer de Herve MG, Durali D, Delfraissy JF, Taoufik Y. Critical role of JC virus-specific CD4 T-cell responses in preventing progressive multifocal leukoencephalopathy. AIDS 2003;17: 1443-9.
23. Koralnilk IJ. Overview of the cellular immunity against JC virus in progressive multifocal leukoencephalopathy. J Neurovirol 2002:8(Suppl 2):59-65.
24. Ehlers S. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J Rheumatol (Suppl) 2005;74:35-9